Thus, in the current study, we attempted to explore how glucocorticoids alter lipid metabolism at the molecular level and examine the potential impact of GLP-1 agonist, LG, in the treatment of DXM-induced NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.